Dark Canyon Labs

March is Colorectal Cancer Awareness Month

Colorectal cancer is the third leading cause of cancer-related deaths in men and women in the United States, and kills over 50,000 people annually. Colorectal cancer can be prevented by getting screened.

Historically, one of the obstacles of getting a screening colonoscopy has been the bad taste and tolerability of the colonoscopy prep, which must be taken prior to the procedure. Dark Canyon Labs has developed a new colonoscopy prep, DCL-101, which is a taste-free pill prep. A Phase 2 clinical trial was successfully completed, with Phase 3 to begin in the near future.

Dark Canyon Labs is determined to make a safe and effective taste-free pill prep available for patients. Our goal is to make the process of prepping for a colonoscopy much easier and to increase colonoscopy screening rates, thereby saving lives. Get screened and prevent colorectal cancer!

For more information, visit the American Society for Gastrointestinal Endoscopy.

Phase 2 Results of Dark Canyon Labs' Novel Pill Prep DCL-101 Selected as one of the "Most Innovative and Impactful Abstracts at ACG 2018"

The American College of Gastroenterology’s (ACG) Innovation & Technology Committee recently selected 22 abstracts as the “Most Innovative and Impactful Abstracts at ACG 2018”, from over 2600 abstracts that were presented at the ACG’s annual Scientific Meeting in Philadelphia, PA in October 2018.

Dark Canyon Labs’ presentation of Phase 2 study results of the Novel Pill Prep, DCL-101, was selected as one of the “Most Innovative and Impactful Abstracts at ACG 2018.”

The ACG Innovation & Technology Committee is a forum that allows members to gather information about new ideas, innovations and technologies in gastroenterology. Selecting the “Most Innovative and Impactful Abstracts at ACG 2018” allowed the Committee to highlight the clinical significance and importance of emerging technologies in gastroenterology.

See the complete ACG report here.